Checkpoint Inhibitor-TKI Combos Effective in RCC

Cancer Discovery

Abstract

Pembrolizumab or avelumab plus axitinib may be effective first-line treatments for clear-cell advanced renal cell carcinoma. In a pair of phase III trials, the checkpoint inhibitor-tyrosine kinase inhibitor combinations extended progression-free survival compared with sunitinib and were associated with relatively manageable side effects.

Citations

Jun 3, 2021·Cancers·Magdalena RauschPatrycja Nowak-Sliwinska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.